MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

Core Viewpoint - MoonLake Immunotherapeutics is set to host a virtual Capital Markets Day on April 29, 2025, to discuss recent financial and clinical milestones, along with future strategic updates [1][2]. Financial Update - The company has secured a non-dilutive financing agreement of up to $500 million with Hercules Capital, enhancing its financial position and supporting clinical and commercial objectives while preserving shareholder value [3]. Clinical Updates - The Phase 3 VELA Program for Hidradenitis Suppurativa (HS) has completed patient recruitment, with management sharing baseline characteristics and comparability to other trials, along with narrowed guidance on the timing of primary endpoint read-out [4]. - An earlier-than-expected interim readout from the Phase 2 LEDA Study in Palmoplantar Pustulosis (PPP) indicates the potential of sonelokimab in the PPP market, further derisking the asset's overall development [5]. Future Strategic Outlook - Insights on market opportunities will be discussed, including recent data analyses, competitor performance, and strategic imperatives for the company [6]. A Q&A session will follow the presentation [6]. Company Overview - MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on sonelokimab, a novel investigational Nanobody targeting inflammatory diseases, particularly HS and psoriatic arthritis, which affect millions globally [8][12]. - The company was founded in 2021 and is headquartered in Zug, Switzerland [8]. About Sonelokimab - Sonelokimab is a humanized Nanobody that selectively binds to IL-17A and IL-17F, inhibiting inflammation [12]. It is being evaluated for multiple indications, including HS and psoriatic arthritis, with ongoing trials demonstrating significant clinical responses [14][16]. Market Opportunity - Hidradenitis Suppurativa affects an estimated 2% of the population, with a projected market opportunity reaching $15 billion by 2035 due to significant unmet medical needs [22]. - Palmoplantar Pustulosis presents a similar challenge, with a high demand for novel therapies to alleviate symptoms [26].